Search results
FMCSA revised its driver physical qualification standards in 49 CFR 391.41(b) to permit individuals with a stable insulin regimen and properly controlled insulin-treated diabetes mellitus (ITDM) to be qualified to operate commercial motor vehicles in interstate commerce.
- Federal Motor Carrier Safety Administration (FMCSA) Eliminates the ...
On September 19, 2018, FMCSA published Qualifications of...
- Medical Regulations and Guidance Resource Links | FMCSA
Provides the requirements for drivers with diabetes mellitus...
- Federal Motor Carrier Safety Administration (FMCSA) Eliminates the ...
What is the current Federal Motor Carrier Safety Administration (FMCSA) diabetes rule? People who operate commercial motor vehicles and have diabetes treated with insulin are subject to rules that reflect modern diabetes management. The rule represents the first update to the Federal Mo-tor Carrier Safety Regulations on diabetes since 1970.
On September 19, 2018, FMCSA published Qualifications of Drivers; Diabetes Standard final rule, which revised the physical qualifications standard for insulin treated diabetes mellitus (ITDM) individuals operating commercial motor vehicles (CMVs) in interstate commerce.
20 lut 2024 · Provides the requirements for drivers with diabetes mellitus who are treated with insulin for control. Resolution of conflicts of medical evaluation. 49 CFR 391.47: Provides the requirements to apply for resolution of a conflict between a driver’s and motor carrier’s medical examiners.
U.S. Department of Transportation. 1200 New Jersey Avenue, SE Washington, DC 20590 855-368-4200
19 wrz 2018 · Federal Motor Carrier Safety Administration (FMCSA), DOT. ACTION: Final rule. SUMMARY: FMCSA revises its regulations to permit individuals with a stable insulin regimen and properly controlled insulin-treated diabetes mellitus (ITDM) to be qualified to operate commercial motor vehicles (CMVs) in interstate commerce.
Individuals with diabetes mellitus treated with insulin for control must self-monitor blood glucose in accordance with the specific treatment plan prescribed by the treating clinician.